-
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner October 10th, 2019, Bangkok, Thailand — Today, Red Herring announced its Top 100 Asia award winners in recognition of the leading private companies from the region, celebrating these startups’ innovations and technologies across their respective industries. Red Herring Top 100 Asia enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1000 privately financed companies each year in the Asia. Since 1996, ...Oct. 15. 2019 -
EOFLOW Chosen as Company of the Year
EOFLOW made it to the 'Top 10 Diabetes Care Solutions Providers - 2019' list and was chosen as the Company of the Year by Medtech Outlook magazine (see the attachment for a reprint). One can read more about it at: https://diabetes-care.medicaltechoutlook.com/vendors/top-diabetes-care-companies.htmlOct. 07. 2019 -
Menarini Diagnostics & EOFlow sign a long term business agreement
EOFlow Co., Ltd. and A. Menarini Diagnostics S.r.l. Enter Commercial Agreement for International Distribution of Innovative Insulin Patch Pump Seoul, South Korea and Florence, Italy 17 September 2019 – EOFlow Co., Ltd., developer of novel wearable drug delivery solutions, and A. Menarini Diagnostics S.r.l., a leading diagnostics company, today announced a partnership to commercialize the Insulin Patch Pump product developed by EOFlow Co., Ltd. “We are very pleased and excited to work with A. Menarini Diagno...Sep. 17. 2019 -
EOFLOW Receives Breakthrough Device Designation from FDA
EOFlow Receives FDA Breakthrough Device Designation on its Integrated Wearable Automated Insulin Delivery System SAN JOSE, USA and SEOUL, South Korea, March 14, 2019 EOFLOW CO., Ltd., an emerging medical device company with offices in Seoul, South Korea and San Jose, California, announced today that its closed loop Automated Insulin Delivery /Artificial Pancreas Device (AID/AP), the EOPancreas System, has received Breakthrough Device Designation by the U.S. Food and Drug Administration. The EOPancreas System is designed to pr...Mar. 14. 2019 -
EOFLOW will be at the 2017 ADA, San Diego (6/9-13)
EOFLOW will exhibit its commercial EOPatch wearable disposable insulin delivery product at the 2017 American Diabetic Association's 77th Scientific Session held in San Diego, 6/9 - 6/13/2017. EOFLOW's booth is 1556. Please contact us in advance if you'd like to arrange a meeting with our marketing team: info@eoflow.comMay. 29. 2017 -
EOFLOW Expands
EOFLOW opens a second office near its current headquarters to accommodate the ever-growing work force. Our engineering and production teams have moved in to the new space.Apr. 25. 2017 -
EOFLOW exhibits at 2017 KIMES
EOFLOW has exhibited its EOPatch wearable disposable insulin pump products at the 2017 Korea International Medical & Hospital Equipment Show (KIMES). The show always attracts a lot of visitors, and this year was no different. Many potential business partners and end users visited our booth, including the minister of Ministry of Health and Welfare, and the head of KFDS.Apr. 06. 2017 -
Meeting with Type 1 Diabetes Community - Again
From time to time, EOFLOW invites type 1 diabetic patients and their family members to come visit the company. Our first such meeting this year was held a few days ago, and we had our friends come from all over the country.Apr. 06. 2017 -
EOFLOW on TV
EOFLOW was featured in an exclusive 30-minute program from SBS-CNBC that covers promising start-up companies in Korea. You can view the program through the link provided below. Unfortunately, the program is in Korean only. http://sbscnbc.sbs.co.kr/read.jsp?pmArticleId=10000844774Feb. 08. 2017 -
EOFLOW closes its Series-B funding
EOFLOW is starting 2017 on a high note: the company successfully closed its Series-B round of funding. Three major venture capital firms invested some $5.5M in this round, including two large firms each managing over $1B funds. With the latest round of funding, combined with the company's current cash reserve and government grants, EOFLOW is well positioned for its first commercial product launch scheduled for later this year, as well as for execution of follow-on product development plans.Jan. 14. 2017 -
EOFLOW to present at the RESI Innovation Challenge
EOFLOW will present at the upcoming RESI Innovation Challenge to be held in San Francisco on January 10, 2017. There were more than 100 applicants to the event, and we're proud to be chosen as one of the 30 finalists. Check us out at: http://www.resiconference.com/innovation-challenge/Dec. 21. 2016 -
EOFLOW unveils its EOPatch design
EOFLOW today unveiled the final design of its first smart wearable insulin pump, EOPatch. The new design is much slimmer than the previously publicized design, with a dimension of 49mm x 32mm x 12.6mm. With the new footprint, EOPatch is the smallest known wearable insulin pump with adjustable basal and bolus delivery. The new design can be found on our website: www.eoflow.comSep. 10. 2016 -
EOPatch submitted for regulatory approval tests
After many years of development and refinements, EOFLOW's smart, disposable wearable insulin pump, EOPatch, has been officially submtted for verification and validation tests on 9/5/2016. We expect to be able to market the product in the global market in 2017.Sep. 07. 2016 -
EOPatch chosen as a next generation medical device 100
EOFLOW's smart disposable wearable insulin pump, EOPatch, has been chosen by the Korean government as one of the twenty devices chosen this year as a part of 'Next Generation Medical Device 100' which are meant to represent the most promising 100 new medical devices for the country. The selected companies will be supported by a group of experts and mentors to help expedite the regulatory approvals. This will ensure a more prompt debut of our product in 2017!Sep. 05. 2016
Healthcare Innovation Park #H2102 Dolma-ro 172 Bundang-gu Seongnam-si Gyeonggi-do Republic of Korea
T (+82) 031-738-0200
F (+82) 031-738-0208
COPYRIGHT ⓒ 2017 EOFLOW CO., LTD. All Rights Reserved.
